A look at the freshness of pharma's pipelines shows that Sanofi's new chief executive has his work cut out, while Lilly and Astrazeneca come up smelling of…
An analysis of the sellside’s consensus forecast changes reveals the winners and losers of 2019.
The first-line Checkmate-9ER study will read out soon, and could show whether two arch rivals can together defeat a common enemy.
Incyte hands across $750m up front and buys $150m of Morphosys equity for rights to the anti-CD19 project.
For Verona’s long-suffering shareholders today brought an unexpected clinical success with ensifentrine.
In the battle between two Kit/PDGFRα kinase inhibitors first blood goes to Blueprint’s avapritinib.
The $1.1bn that Lilly is paying for lebrikizumab looks low ball, but competing against Dupixent will not come cheap. And then there are the Roche payments.
Pfizer's abrocitinib heads against Dupixent in atopic dermatitis, while Myovant hopes to raise its Spirits.
For $3m Verastem adds to its pipeline another asset that a bigger company had given up on.